Clinical Centers for the HALT-Polycystic Kidney Disease Trials (U01)

HALT-多囊肾病试验临床中心 (U01)

• 批准号: 7920520
• 负责人: RONALD D PERRONE
• 金额: $ 10.82万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-21 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7920520
• 关键词: Adherence; Adverse effects; Albuminuria; Aldosterone; Antihypertensive Agents; Autosomal Dominant Polycystic Kidney; Blood Pressure; Cardiovascular system; Cessation of life; Clinical; Clinical Trials; Combined Modality Therapy; Dialysis procedure; Disease Progression; End stage renal failure; Enrollment; Excretory function; Frequencies; Glomerular Filtration Rate; Goals; Hospitalization; Hypotension; Individual; Kidney; Kidney Diseases; Kidney Failure; Left Ventricular Mass; Magnetic Resonance Imaging; Measures; Medical; Pain; Participant; Patients; Pharmaceutical Preparations; Phase; Polycystic Kidney Diseases; Principal Investigator; Procedures; Protocols documentation; Quality of life; Questionnaires; Randomized; Renal Blood Flow; Renal function; Research Personnel; Site; Symptoms; System; Time; Transplantation; Upper arm; blood pressure regulation; design; follow-up; meetings; safety study; urinary

DESCRIPTION (provided by applicant): The purpose of this limited competition is to continue patient follow-up and complete the two ongoing HALTPolycystic Kidney Disease (PKD) clinical trials. Tufts-NEMC and the subcontracted site at BIDMC are two of seven patient enrolling sites for HALT-PKD. The HALT-PKD Trials are comprised of two studies (A & B) and are both currently in the patient enrollment phase. HALT-PKD Study A is evaluating the impact of reninangiotensin- aldosterone system (RAAS) blockade on progression of disease in 548 hypertensive PKD patients with estimated glomerular filtration rate (GFR) > 60ml/min/1.73 m2. In Study A, the effect of study medication on structural progression at two different levels of blood pressure control is assessed using a 2x2 factorial design. Accordingly, 548 hypertensive ADPKD participants are randomized to one of four study arms: 1) combination ACE-I/ARB with standard blood pressure (BP) control (systolic 120-130 and diastolic 70-80 mm Hg); 2) ACE-I monotherapy with standard BP control; 3) combination ACEI/ ARB treated to a low BP target (systolic 95-110 and diastolic 60-75 mm Hg); and 4) ACE-I treated to the low BP goal. Other antihypertensive agents are added as needed to meet the BP goals. The primary endpoint of the study is the percent change in total kidney volume, as measured by magnetic resonance imaging (MRI) over time. HALT-PKD Study B is evaluating the impact of RAAS blockade on progression of disease in 472 hypertensive PKD patients with estimated GFR 30-60 ml/min/1.73 m2. The primary endpoint of Study B is a composite endpoint of time to the 50% reduction of baseline estimated GFR, ESRD (initiation of dialysis or preemptive transplant), or death. All 472 hypertensive ADPKD participants are treated to a standard level of blood pressure control (systolic 110-130 mm Hg and diastolic 80 mm Hg), with addition of other antihypertensive agents as needed. This application will describe in detail the two participating clinical centers including the investigators and study teams; adherence to the study protocol; quality and safety of study procedures; and efforts being made to achieve the targeted recruitment goal of 137 study A and 118 study B subjects.

描述（由申请人提供）：本次有限竞赛的目的是继续患者随访并完成两项正在进行的HALT多囊肾病（PKD）临床试验。Tufts-NEMC和BIDMC的分包研究中心是HALT-PKD的七个患者入组研究中心中的两个。HALT-PKD试验由两项研究（A和B）组成，目前均处于患者招募阶段。HALT-PKD研究A是在548例估计肾小球滤过率（GFR）> 60 ml/min/1.73 m2的高血压PKD患者中评估肾素血管紧张素-醛固酮系统（RAAS）阻断对疾病进展的影响。在研究A中，使用2x2析因设计评估研究药物对两种不同血压控制水平下结构进展的影响。因此，548名高血压ADPKD参与者被随机分配到四个研究组之一：1）ACE-I/ARB联合标准血压（BP）控制（收缩压120-130 mm Hg，舒张压70-80 mm Hg）; 2）ACE-I单药治疗与标准血压控制; 3）ACEI/ ARB联合治疗达到低血压目标（收缩压95-110 mmHg，舒张压60-75 mmHg）;和4）ACE-I治疗至低BP目标。根据需要添加其他抗高血压药物以达到BP目标。研究的主要终点是通过磁共振成像（MRI）测量的肾脏总体积随时间的百分比变化。HALT-PKD研究B在472例估计GFR 30-60 ml/min/1.73 m2的高血压PKD患者中评价RAAS阻断对疾病进展的影响。研究B的主要终点是至基线估计GFR降低50%的时间、ESRD（开始透析或抢先移植）或死亡的复合终点。所有472名高血压ADPKD参与者均接受标准血压控制水平（收缩压110-130 mm Hg，舒张压80 mm Hg）治疗，并根据需要添加其他抗高血压药物。本申请将详细描述两个参与临床中心，包括研究者和研究团队;研究方案依从性;研究程序的质量和安全性;以及为实现137例研究A和118例研究B受试者的目标招募目标所做的努力。